243 related articles for article (PubMed ID: 29848909)
1. Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins.
Hori Y; Shibuya K
Med Mycol J; 2018; 59(2):E31-E40. PubMed ID: 29848909
[TBL] [Abstract][Full Text] [Related]
2. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.
Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164462
[No Abstract] [Full Text] [Related]
3. Mechanisms of echinocandin antifungal drug resistance.
Perlin DS
Ann N Y Acad Sci; 2015 Sep; 1354(1):1-11. PubMed ID: 26190298
[TBL] [Abstract][Full Text] [Related]
4. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Beyda ND; Lewis RE; Garey KW
Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
[TBL] [Abstract][Full Text] [Related]
5. Echinocandin Resistance in Candida.
Perlin DS
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S612-7. PubMed ID: 26567278
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin: when and how? The microbiologist's view.
Mayr A; Aigner M; Lass-Flörl C
Mycoses; 2012 Jan; 55(1):27-35. PubMed ID: 21668518
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives on echinocandin class drugs.
Perlin DS
Future Microbiol; 2011 Apr; 6(4):441-57. PubMed ID: 21526945
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of anidulafungin. Comparison with the activity of other echinocandins].
Martín Mazuelos E; Rodríguez-Tudela JL
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():7-13. PubMed ID: 19572429
[TBL] [Abstract][Full Text] [Related]
9. Molecular Confirmation of the Relationship between Candida guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility.
Dudiuk C; Macedo D; Leonardelli F; Theill L; Cabeza MS; Gamarra S; Garcia-Effron G
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242659
[No Abstract] [Full Text] [Related]
10. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.
Perlin DS
Drugs; 2014 Sep; 74(14):1573-85. PubMed ID: 25255923
[TBL] [Abstract][Full Text] [Related]
11. Sequencing of
Arrieta-Aguirre I; Menéndez-Manjón P; Cuétara MS; Fernández de Larrinoa I; García-Ruiz JC; Moragues MD
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29229638
[No Abstract] [Full Text] [Related]
12. Resistance to echinocandin-class antifungal drugs.
Perlin DS
Drug Resist Updat; 2007 Jun; 10(3):121-30. PubMed ID: 17569573
[TBL] [Abstract][Full Text] [Related]
13. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species.
Johnson ME; Katiyar SK; Edlind TD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3774-81. PubMed ID: 21576441
[TBL] [Abstract][Full Text] [Related]
14. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Zaragoza O; Bouza E; Guinea J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
[TBL] [Abstract][Full Text] [Related]
15. Novel FKS mutations associated with echinocandin resistance in Candida species.
Garcia-Effron G; Chua DJ; Tomada JR; DiPersio J; Perlin DS; Ghannoum M; Bonilla H
Antimicrob Agents Chemother; 2010 May; 54(5):2225-7. PubMed ID: 20145084
[TBL] [Abstract][Full Text] [Related]
16. [The mechanisms of resistance to echinocandin class of antifungal drugs].
Niimi K; Niimi M
Nihon Ishinkin Gakkai Zasshi; 2009; 50(2):57-66. PubMed ID: 19430179
[TBL] [Abstract][Full Text] [Related]
17. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.
Wiederhold NP; Lewis JS
Expert Opin Pharmacother; 2007 Jun; 8(8):1155-66. PubMed ID: 17516879
[TBL] [Abstract][Full Text] [Related]
18. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
Garcia-Effron G; Katiyar SK; Park S; Edlind TD; Perlin DS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2305-12. PubMed ID: 18443110
[TBL] [Abstract][Full Text] [Related]
19. Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
Pfaller MA; Messer SA; Rhomberg PR; Borroto-Esoda K; Castanheira M
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533234
[TBL] [Abstract][Full Text] [Related]
20. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.
Lackner M; Tscherner M; Schaller M; Kuchler K; Mair C; Sartori B; Istel F; Arendrup MC; Lass-Flörl C
Antimicrob Agents Chemother; 2014 Jul; 58(7):3626-35. PubMed ID: 24733467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
